Dana-Farber Cancer Institute: Adenocarcinoma trials

The registry lists 10 Adenocarcinoma studies with Dana-Farber Cancer Institute as lead sponsor. 0 are open to participants now and 4 have results posted.

Early Phase 1 1Phase 1 1Phase 2 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic AdenocarcinomaTerminatedNCT03469258Phase 2Results posted
• Incorporating MR Imaging Into Prostate Radiotherapy Treatment PlanningCompletedNCT02470910Not applicableResults posted
• Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateCompletedNCT02268175Phase 2Results posted
• Sunitinib in Never-Smokers With Lung AdenocarcinomaCompletedNCT01829217Phase 2Results posted
• Whole-Exome Sequencing (WES) of Cancer PatientsCompletedNCT02127359
• OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the PancreasWithdrawnNCT01600807Phase 1/2
• Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT00215514Early Phase 1
• Vinorelbine in Unresectable or Metastatic Esophageal and Gastric AdenocarcinomaCompletedNCT00215462Phase 2
• Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal CancerCompletedNCT00165490Phase 2
• Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or EsophagusCompletedNCT00165191Phase 2